A Synthetic Small Molecule F240B Decreases NLRP3 Inflammasome Activation by Autophagy Induction

Conjugated polyenes are a class of widely occurring natural products with various biological functions. We previously identified 4-hydroxy auxarconjugatin B (4-HAB) as anti‐inflammatory agent with an IC50 of ~20 µM. In this study, we synthesized a new anti‐inflammatory 4-HAB analogue, F240B, which has an IC50 of less than 1 µM. F240B dose-dependently induced autophagy by increasing autophagic flux, LC3 speck formation and acidic vesicular organelle formation. F240B inhibited NACHT, LRR and PYD domain-containing protein 3 (NLRP3) inflammasome activation through autophagy induction. In a mechanistic study, F240B inhibited interleukin (IL)-1β (IL-1β) precursor expression, promoted degradation of NLRP3 and IL-1β, and reduced mitochondrial membrane integrity loss in an autophagy-dependent manner. Additionally, F240B inhibited apoptosis-associated speck-like protein containing a CARD (ASC) oligomerization and speck formation without affecting the interaction between NLRP3 and ASC or NIMA-related kinase 7 (NEK7) and double-stranded RNA-dependent kinase (PKR). Furthermore, F240B exerted in vivo anti-inflammatory activity by reducing the intraperitoneal influx of neutrophils and the levels of IL-1β, active caspase-1, IL-6 and monocyte chemoattractant protein-1 (MCP-1) in lavage fluids in a mouse model of uric acid crystal-induced peritonitis. In conclusion, F240B attenuated the NLRP3 inflammasome through autophagy induction and can be developed as an anti-inflammatory agent in the future.


INTRODUCTION
The intracellular sensor, NACHT, LRR, and PYD domaincontaining protein 3 (NLRP3) inflammasome, is a multimeric protein complex composed of a sensor NLRP3, an adaptor protein apoptosis-associated speck-like protein (ASC) and an effector caspase-1. Activation of the NLRP3 inflammasome is a two-step process that involves priming and activation. During priming, transcriptional upregulation of NLRP3 and the proinflammatory cytokines interleukin (IL)-1b (IL-1b) precursor (proIL-1b) is induced by recognition of pathogen-associated molecular patterns by pattern recognition receptors (1). The major signaling pathways involved in the priming stage of the NLRP3 inflammasome are reactive oxygen species (ROS), the mitogen-activated protein kinase (MAPK) pathway and nuclear factor kappa B (NF-kB)-associated pathways (1,2). During the activation stage, damage or danger-associated molecular patterns, such as bacterial toxins and extracellular ATP, lead to the assembly of the NLRP3 inflammasome which in turn result in the activation of cysteine protease caspase-1 (1,3) and the conversion of proIL-1b to mature IL-1b by the active caspase-1.
Since NLRP3 plays a significant role in innate immunity, dysregulated activation results in inflammatory conditions such as atherosclerosis, Type-II diabetes, gout and various neurodegenerative disorders (3). Anti-inflammatory drugs such as colchicines and glucocorticoids, are commonly used to treat NLRP3-related inflammatory diseases, however these drugs exhibit severe side-effects which limits their applications (4). Hence new therapeutics that potentially inhibit NLRP3 with minimal side-effects need to be developed.
Conjugated polyenes occurring in natural products have been shown to exhibit antibacterial, antifungal and antitumor activities (5). Despite their biological significance, the usage of these compounds as therapeutics has been limited because of their availability. Presently, the only known sources of natural polyenes are bacteria and fungi and the amounts of polyenes that can be obtained from them are very low. Chemical synthesis offers an alternative source to these compounds. In our earlier studies, we have successfully synthesized a library of analogues that was derived from a naturally occurring polyene (6)(7)(8). We found that one of the analogous, 4-hydroxy auxarconjugatin B (4-HAB), a polyenylpyrrole derivative, inhibits NLRP3 inflammasome activation by inhibiting ASC oligomerization, lysosomal rupture and mitochondrial damage in an autophagy-dependent manner. 4-HAB was also shown to ameliorate uric acid crystal-mediated peritonitis in mice (9).

General Synthesis Procedures
All chemical reagents and solvents were obtained from Sigma Aldrich, Merck, Alfa Aesar, Fluka or TCI and were used without further purification. Microwave-assisted reactions were performed using the Biotage Initiator microwave synthesizer. TLC were performed on precoated silica plated (Merck silica gel 60, F254) and visualized with UV or stained with phosphomolybdic acid, alkaline potassium permanganate stain. Flash chromatography was performed on silica (Merck, 70-230 mesh). 1 H, 13 C and 31 P NMR spectra were measured on a Bruker AMX 300, 500 or 400 spectrometer (Supporting Information). Chemical shifts were reported in parts per million (d) relative to the tetramethylsilane standard. Mass spectra were performed on a Finnigan/MAT LCQ mass spectrometer under either electron spray ionization (ESI) or electron impact (EI) techniques.

Synthesis of 2
Synthesis of 2 was performed according to the procedure reported by Fang et al. (6). The compound was obtained in 28% yield (over 4 steps).

Synthesis of 3
The crude mixture of 2 was then taken up in DMSO (5 ml), and K 2 CO 3 (645 mg, 4.68 mmol) and Et 2 SO 4 (264 µl, 2.06 mmol) were added. The reaction was stirred at room temperature for 2h. The mixture was diluted in ethyl acetate and washed with water 3 times. The organic layer was dried over MgSO 4 , filtered and concentrated. Flash chromatography of the crude mixture (hexane: ethyl acetate = 2:1) gave 3 (257 mg, 65%) as a white solid. 1

Synthesis of 8
Compound 8 was prepared from trimethylborate and propargyldehyde diethyl acetal using the procedure reported by Feng et al. (6). It was obtained in 35% yield (over 4 steps) (Scheme 2).

Synthesis of F240B
A round bottom flask was charged with degassed NMP (1 ml) and 1 (126mg, 0.401 mmol), 8 (283 mg, 0.603 mmol), AsPh 3 (14.75 mg, 48.2 µmol) and Pd(PPh 3 ) 4 (11 mg, 12 µmol) were added sequentially. The reaction was stirred at room temperature for 6h. The mixture was then diluted in Et 2 O and washed with water 3 times followed by brine. The organic layer was dried over MgSO 4 , filtered and concentrated and then taken up in CH 3 CN. The CH 3 CN layer was then washed with hexane 3 times and then concentrated. Flash chromatography of the crude mixture (hexane:ethyl acetate = 2:1) through a short plug of silica gave 10 (62 mg, 38%) which was used immediately in the subsequent step. To a solution of 9 (64 mg, 0.225 mmol) in THF (0.4 ml) was added AsPh 3 (4.6 mg, 15 µmol), 10 (62 mg, 0.15 mmol), Pd (PPh 3 ) 4 (2.7 mg, 3 µmol) and 10% KOH (0.17 ml, 0.3 mmol) sequentially. The reaction was stirred at room temperature for 30 min. The mixture was quenched with NH 4 Cl, taken up in ethyl acetate and washed with water 3 times. The organic layer was dried over MgSO 4 , filtered and concentrated. Flash chromatography of the crude mixture (hexane:ethyl acetate = 3:1) over a short plug of silica gave 11 (54 mg, 74%) as a red solid. 11 (164 mg, 0.333 mmol) was then taken up in THF (13 ml) and TBAF (1M in THF, 0.667 ml, 0.667 mmol) was added dropwise at 0℃. The reaction was stirred at room temperature for 1h. The mixture was diluted in ethyl acetate and washed with water 3 times, followed by brine. The organic layer was dried over MgSO 4 , filtered and concentrated. Flash chromatography of the crude mixture (hexane:ethyl acetate = 3:1) over a short plug of silica gel gave F240B (104 mg, 76%) as a red solid (Scheme 3). 1 13

Bacterial Strains and Infection
Salmonella (ATCC 14028) were purchased from the American Type Culture Collection (Rockville, MD), and cultured on Salmonella Shigella agar (Creative, TW) at 37°C in a 5% CO 2 incubator. The number of viable Salmonella was determined by a colorimeter (M6+ Colorimeter, Metertech). J774A.1 macrophages were primed with 1 µg/ml LPS for 5 h followed by treated with 1 µM F240B for 3 h. Cells were infected 2 h with Salmonella at a multiplicity of infection (MOI) of 20.

Lactate Dehydrogenase Release Assay
To determine the cytotoxicity of F240B, J774A.1 macrophages were incubated with 0.1-1 µM F240B, lysis buffer (maximum LDH release) or 10% H 2 O (spontaneous LDH release) for 3.5 or 24.5 h. Cytotoxicity was determined by measuring the LDH levels in culture medium using the CytoScan LDH Cytotoxicity Assay kit as described previously (9). The cytotoxicity % was calculated as 100 X (sample OD − spontaneous OD)/(maximum OD -spontaneous OD).

ASC Oligomerization and Speck Formation
To detect ASC oligomerization, J774A.1 macrophages were incubated with 1 µg/ml LPS for 5 h followed by incubation with with 1 µM F240B for 3 h. Cells were then incubated with 5 mM ATP for 0.5 h and lysed by lysis buffer. After centrifuge, the pellets were cross-linked with 2 mM disuccinimidylsuberate at 37°C for 30 min and subsequent analyzed by Western blotting (9). To detect ASC speck formation, ASC-expressing J774A.1 macrophages were incubated with 1 µg/ml LPS for 5 h followed by incubated with 1 µM F240B for 3 h. Cells were then incubated with 5 mM ATP for 0.5 h. Cells were fixed in 4% paraformaldehyde for 0.5 h and the fluorescent signals were acquired by confocal microscope.

Immunoprecipitation-Western Blotting Assay
To detect the binding between NLRP3 and ASC, NEK7 and PKR, J774A.1 macrophages were incubated with 1 µg/ml LPS for 5 h followed by incubation with 1 µM F240B or 0.1 µM MCC950 for 3 h. Cells were then incubated with 5 mM ATP for 0.5 h and lysed by lysis buffer. Prepared a 500 ml mixture containing 500 mg protein and 1 mg NLRP3 or ASC antibody. Incubated the mixture with gentle rocking at 4°C for overnight followed by adding 20 ml protein A/G agarose bead and gentle rocking at 4°C for additional 1 h. After centrifuge, the supernatant was removed and the pellet was subsequent analyzed by Western blotting against NLRP3, NEK7, and PKR, respectively.

Statistical Analysis
Because of the sample size is small and the data is not normal distribution in this study, the non-parametric Mann-Whitney Utest was used to analyze changes between two groups. All statistical analyses were performed using Prism v5.0 (Graphpad software). P values less than 0.05 were considered to be statistically significant. Intermediates 8 and 9 were synthesized using the procedure reported previously (6,11).

F240B Induces Autophagy
Autophagy is the cellular protective mechanism that inhibits the NLRP3 inflammasome (12). To investigate the effect of F240B on autophagy induction, J774A.1 macrophages were incubated for 3-24 h with 0.3 µM F240B or for 4 h with 0.1 µM rapamycin (an autophagy inducer). The expression levels of the autophagy markers LC3 and p62 in the lysates were measured by Western blotting. We found that the LC3-II expression level was increased by rapamycin or F240B after 3 h of treatment and extended to 24 h ( Figure 1A). The p62 protein expression level was reduced by rapamycin or F240B after 3 h and 6 h of treatment and recovered after 12 h of treatment, indicating autophagic flux ( Figure 1B). In addition, incubation of the cells with 0.1-1 µM F240B for 3 h reduced p62 protein expression in a dosedependent manner ( Figure 1C). Furthermore, 1 µM F240B treatment for 3 h or 0.1 µM rapamycin treatment for 4 h induced autophagosome (LC3-GFP specks) formation in J774A.1 macrophages that stably expressed GFP-LC3 fusion protein ( Figure 1D). To confirm the induction of autophagy by F240B, J774A.1 macrophages were incubated for 3 h with 1 µM F240B. The cells were stained with the fluorescent autophagy indicators MDC and AO, and the fluorescent signals were acquired by confocal microscopy. We found that the fluorescent signals of MDC and AO were significantly increased by F240B treatment ( Figure 1E). These results indicate that F240B is a potent autophagy inducer in macrophages.

F240B Inhibits the NLRP3 Inflammasome-Derived IL-1b Secretion
Since F240B treatment for 3 h significantly induced autophagy in macrophages (Figure 1), we asked whether F240B could inhibit the NLRP3 inflammasome through autophagy induction. To address this hypothesis, LPS-primed J774A.1 macrophages were incubated for 0.5 h (no autophagy induction) or 3 h (autophagy induced) with F240B, followed by treatment with the NLRP3 activator ATP or nigericin for 0.5 h. NLRP3 inflammasome activation was analysed by measuring IL-1b secretion. We found that LPS priming did not significantly induce IL-1b secretion, and ATP (Figure 2A) or nigericin ( Figure 2B) significantly induced IL-1b secretion. Notably, we demonstrated that 3 h but not 0.5 h F240B treatment reduced IL-1b secretion in a dosedependent manner in ATP- (Figure 2A) and nigericin-activated cells ( Figure 2B). Under the same conditions, neither 0.5 h nor 3 h F240B treatment affected TNF-a secretion, which was independent of the NLRP3 inflammasome ( Figures 2C, D). In addition, F240B also reduced IL-1b secretion mediated by MSU and SiO 2 , which are also NLRP3 inflammasome activators ( Figure 2E). To rule out the possibility that F240B-mediated IL-1b inhibition was due to cytotoxic effects, we further investigated the cytotoxicity of F240B in J774A.1 macrophages by LDH release assay. F240B treatment for 3.5 h did not increase LDH release, but F240B slightly increased LDH release at 1 µM after 24.5 h of treatment ( Figure 2F). These results indicated that F240B-inhibited IL-1b secretion was not due to a reduction in cell viability. The inhibitory activity of F240B on IL-1b was confirmed in BMDMs, human THP-1 macrophages and PBMCs as treatment reduced the IL-1b levels in ATP-or nigericin-activated BMDMs ( Figure 3A), THP-1 macrophages ( Figure 3B) and PBMCs ( Figure 3C). In addition, we investigate whether F240B could inhibits the activation of other inflammasomes. We found that F240B reduced IL-1b secretion in J774A.1 macrophages transfected with LPS, MDP or poly(dA: dT), which activates non-canonical-, NLRP3-and the absent in melanoma 2 (AIM2)-inflammasome, respectively ( Figure 3D). However, F240B did not reduce the IL-1b secretion in J774A.1 macrophages infected with Salmonella or transfected with FLA-ST, which activate NLR family CARD domain containing 4 (NLRC4) inflammasome ( Figure 3D). These results indicated that F240B not only inhibited the NLRP3 inflammasome but also inhibited non-canonical-and AIM2-inflammasome.

F240B Inhibits the NLRP3 Inflammasome Through Autophagy Induction
To confirm the inhibitory activity of F240B on the NLRP3 inflammasome, we investigated the effect of F240B on IL-1b secretion and caspase-1 activation using Western blotting. We found that F240B treatment for 3 h significantly reduced ATPinduced IL-1b secretion and caspase-1 activation in LPS-primed J774A.1 macrophages ( Figure 4A). Activation of the NLRP3 inflammasome induces caspase-1-dependent cell death (pyroptosis) that is characterized by the loss of cell membrane integrity. ATP treatment significantly induced the extracellular release of NLRP3 and ASC in LPS-primed J774A.1 cells, indicating the loss of cell membrane integrity ( Figure 4B). release of ASC and NLRP3 ( Figure 4B), indicating that F240B reduced pyroptosis. To investigate the involvement of autophagy in F240B-mediated NLRP3 inflammasome inhibition, the autophagy inhibitor 3-MA was used to test whether autophagy inhibition abolished F240B-mediated IL-1b downregulation. We found that 3-MA preincubation abolished F240B-mediated IL-1b downregulation in ATP-or nigericin-activated cells ( Figure  4C). The role of autophagy in F240B-mediated NLRP3 inflammasome inhibition was confirmed by LC3-knockout in J774A.1 macrophages, as F240B did not inhibit IL-1b secretion in ATP-or nigericin-activated LC3-knockout cells ( Figure 4D).
These results indicate that F240B inhibits the NLRP3 inflammasome through autophagy induction.

Activation of Autophagy by F240B Inhibits NF-kB Activation and ProIL-1b Expression
Induction of proIL-1b and NLRP3 proteins by LPS-mediated priming signaling is the crucial step for NLRP3 inflammasome activation (2). We found that LPS treatment significantly induced proIL-1b and NLRP3 expression in J774A.1 macrophages; notably, F240B significantly reduced proIL-1b but not NLRP3 expression ( Figure 5A). To dissect the underlying molecular mechanisms of F240B-mediated proIL-1b inhibition, the important priming signals induced by LPS were evaluated. We found that LPS treatment significantly increased NF-kB transcriptional activity as analyzed by the NF-kB reporter assay, and this effect was inhibited by F240B in a dose-dependent manner ( Figure 5B). F240B also inhibited the phosphorylation level of IkBa in LPS-activated J774A.1 macrophages, confirming that F240B inhibits NF-kB ( Figure  5C). In addition, we investigated the effect of F240B on LPSmediated ROS production, which is an upstream priming signal that regulates proIL-1b expression in J774A.1 macrophages (2). We found that LPS treatment significantly increased intracellular ROS production, as analyzed by staining with the ROS indicator H 2 DCFDA; however, F240B did not reduce ROS production in J774A.1 macrophages ( Figure 5D). Moreover, F240B also did not affect the phosphorylation levels of ERK1/2, JNK1/2 or p38 ( Figure 5E), which are also priming signal in LPS-activated J774A.1 macrophages (2). Finally, we found that F240Bmediated proIL-1b downregulation was associated with autophagy induction, as the inhibitory effect of F240B on proIL-1b was reduced in LC3 knockout J774A.1 macrophages ( Figure 5F).

Activation of Autophagy by F240B Reduced the Protein Stability of NLRP3 and ProIL-1b
It has been demonstrated that autophagy is involved in the cellular degradation of NLRP3 inflammasome components (13,14). To investigate whether F240B affects the protein stability of NLRP3 and proIL-1b, J774A.1 macrophages were incubated with LPS for 5 h followed by incubation with F240B or DMSO (vehicle) for 3 h. The cells were then treated with the translation inhibitor cycloheximide (CHX) for 3-12 h. The protein expression levels of NLRP3 and proIL-1b were measured by Western blotting. We found that NLRP3 protein was not significantly degraded after 3-12 h CHX treatment in DMSO-treated cells; however, NLRP3 protein was significantly degraded after 12 h CHX treatment in F240B-treated cells ( Figure 6A). In addition, proIL-1b protein was degraded in DMSO-treated cells in a time-dependent manner, and this effect was enhanced by F240B ( Figure 6A). To investigate whether the autophagy-dependent pathway was involved in F240B-mediated degradation of NLRP3 and proIL-1b, the autophagy inhibitor 3-MA was used. We found a substantial accumulation of NLRP3 and proIL-1b protein levels upon treatment with 3-MA ( Figure  6B). These results indicate that the autophagy-dependent pathway contributes to the degradation of NLRP3 and proIL-1b in F240B-treated cells.

Activation of Autophagy by F240B Limits Mitochondrial Integrity Loss
Induction of proIL-1b and NLRP3 is not sufficient to activate the NLRP3 inflammasome. Fully activating the NLRP3 inflammasome requires an additional stimulus that provides activation signals (15). Mitochondrial dysfunction is an important activation signal for the NLRP3 inflammasome (16). We found that ATP induced mitochondrial membrane integrity loss (evidenced by reduced MitoTracker Deep Red staining; R2 fraction) in J774A.1 macrophages, and this effect was reduced by F240B ( Figure 7A). Importantly, the autophagy inhibitor 3-MA limited the protective effect of F240B on mitochondria ( Figure 7A).
In addition, the protective effect of F240B on mitochondria was also reduced in LC3 knockout J774A.1 macrophages compared to that in wild-type cells ( Figure 7B). These results indicate that activation of autophagy by F240B limits mitochondrial integrity loss and reduces NLRP3 inflammasome activation.

F240B Inhibits ASC Oligomerization
Activation of the NLRP3 inflammasome is required the formation of high-molecular-weight ASC oligomers (17). To investigate whether F240B inhibits the NLRP3 inflammasome by reducing ASC oligomerization, the effect of F240B on ASC oligomerization was analysed by ASC speck formation and ASC cross-linking assays. We found that ATP induced ASC oligomerization, as evidenced by the formation of ASC specks in ASC-GFP-expressing J774A.1 macrophages, and this effect was reduced by F240B ( Figure 8A). In addition, the inhibitory effect of F240B on ASC oligomerization was confirmed by ASC cross-linking Western blotting assays ( Figure 8B). These results indicate that F240B inhibits ASC oligomerization. NLRP3 physically interacts with ASC, NEK7 and PKR, forming a protein complex that leads to NLRP3 inflammasome activation. Using immunoprecipitation and Western blotting assays, we found that the interactions between NLRP3 and ASC ( Figure 8C) or NEK7 ( Figure 8D) and PKR ( Figure 8E) were not affected by F240B.

F240B Inhibits NO, COX-2, and IL-6 Expression
To investigate whether F240B also inhibits the traditional inflammatory response independent of the NLRP3 inflammasome, the effect of F240B on the expression levels of NO, IL-6, TNF-a and COX-2 in LPS-activated J774A.1 macrophages was studied. We found that F240B inhibited LPSinduced COX-2 ( Figure 9A), NO ( Figure 9B) and IL-6 ( Figure 9C) expression in a dose-dependent manner; however, LPS-induced TNF-a expression was not affected by F240B ( Figure 9D). These results indicate that F240B not only inhibits the NLRP3 inflammasome but also reduces the traditional inflammatory response in macrophages. The ELISA data expressed as mean ± SD of three separate experiments. *, ** and *** indicate a significant difference at the level of p < 0.05, p < 0.01 and p < 0.001, respectively, compared to MSU crystal-injected mice. ### indicates a significant difference at the level of p < 0.001 compared to control mice.

F240B Inhibits the NLRP3 Inflammasome and Inflammation in a Mouse Model of Gouty Inflammation
We investigated the in vivo anti-inflammatory activity of F240B using an NLRP3 inflammasome-associated MSU crystal-induced mouse peritonitis model (18). We found that intraperitoneal injection of MSU crystals increased neutrophil recruitment in the peritoneum, and this effect was significantly reduced by intraperitoneal injection of F240B (20 mg/kg body weight) and colchicine (1 mg/kg body weight) ( Figure 10A). MSU crystal injection also increased the levels of IL-1b and active caspase-1 in the peritoneal lavage fluid, and these effects were reduced by F240B and colchicine ( Figure 10B). In addition, F240B also reduced the levels of IL-6 and MCP-1 in the peritoneal lavage fluid of MSU crystal-injected mice ( Figure 10C). These results indicate that F240B limits NLRP3 inflammasome activation and inflammation in vivo.

DISCUSSION
Autophagy is a catabolic cellular homeostatic process that is conserved across mammalian cell types. This self-destructive process is intended to ward off intracellular misfolded proteins and damaged organelles to maintain genome stability and energy balance in the cells. Autophagy is a cell survival mechanism that fights cellular stress, which otherwise results in cell death (19). Studies have shown that autophagy deficiency leads to extensive cellular stress and genome damage (20) and is a crucial bactericidal mechanism that drives bacteria-containing phagosomes to lysosomes for degradation (21). Thus autophagy plays important roles in the immune response. Earlier studies have shown that autophagy is controlled by a broad range of proteins encoded by autophagy-related genes, such as LC3, which is a common marker used for monitoring autophagosomes (12). Accumulating evidence has demonstrated that autophagy negatively regulates NLRP3 inflammasome activation (22). In this study, the autophagyinducing ability of F240B was demonstrated by analyzing the autophagic degradation of p62, accumulation of LC3-II, LC3 speck formation and formation of acidic vesicular organelles ( Figure 1). Autophagy inhibits the NLRP3 inflammasome by removing damaged mitochondria, which produces activation signals, including mitochondrial ROS and oxidized mitochondrial DNA (16,23). We found that F240B inhibited the NLRP3 inflammasome by preserving mitochondrial integrity in an autophagy-dependent manner (Figure 7). Autophagy also inhibits the NLRP3 inflammasome by promoting the degradation of the inflammasome components NLRP3 and proIL-1b (13,14). Although F240B did not inhibit NLRP3 expression, it significantly inhibited proIL-1b expression ( Figure 5A). Notably, F240Bmediated proIL-1b downregulation was reversed by LC3 knockout (Figure 5F), indicating that autophagy promotes the degradation of proIL-1b in F240B-treated cells. It has been demonstrated that a low level of ROS positive regulate the priming signal of the NLRP3 inflammasome and promote NLRP3 inflammasome activation; however, Erttmann and Gekara demonstrated that a high level of ROS release by Streptococcus pneumonia increased the oxidative levels of the inflammasome components ASC and caspases and inhibited the NLRP3 inflammasome (24). These results may partially explain why F240B inhibited the NLRP3 inflammasome, but increased ROS production in LPS-activated macrophages ( Figure 5D). In the NLRP3 inflammasome, the adaptor protein ASC plays a key role in NLRP3 inflammasome assembly by interacting with NLRP3 via an N-terminal pyrin domain and recruiting procaspase-1 via a C-terminal caspase recruitment domain (25). Upon activation, ASC bridges NLRP3 and caspase-1 to form ternary inflammasome complexes, and oligomerization of ASC into filaments and the formation of an ASC speck is a critical step in NLRP3 inflammasome activation (17,26). Thus, disruption of inflammasome complex assembly by targeting ASC is a novel strategy to inhibit the NLRP3 inflammasome (27). In our current study, we demonstrated that F240B inhibited ASC oligomerization and speck formation; however, F240B did not affect the interaction between ASC and NLRP3 ( Figure 8). These results suggest that F240B binds to the amino acid residues in ASC, which is critical for ASC polymerization and fibril extension, but does not bind to the site that recruits NLRP3 (28). In addition, two NLRP3 binding proteins, NEK7 and PKR, have been shown to positively regulate the activation of the NLRP3 inflammasome (29,30). NEK7 acts downstream of potassium efflux to specifically regulate NLRP3 inflammasome activation, as NEK7 knockout results in reduced caspase-1 activation and IL-1b release in NLRP3-activated macrophages but not in NLRC4-or AIM2-activated macrophages (29). Unlike NEK7, PKR broadly regulates inflammasome activation by physically interacting with NLRP3, NLRP1, NLRC4 and AIM2 (30). However, in this study, we found that the NLRP3-NEK7 and NLRP3-PKR interactions were unaltered by the presence of F240B (Figure 8). The molecular mechanism by which F240B interrupts ASC oligomerization is a wide platform that remains to be investigated.
Over the past decade, NLRP3 inflammasome has become a promising molecular target in the fight against inflammatory diseases (1). Research efforts have focused on understanding the pathogenic roles of the NLRP3 inflammasome in metabolic syndromes, cardiovascular diseases and neurologic disorders (31).
In our current study we demonstrated that F240B inhibits NLRP3 inflammasome in macrophages. Although we demonstrated that F240B ameliorates MSU crystal-induced peritonitis in a mouse model (Figure 10), the limitation of this study is the lack of pathophysiological relevant evaluation for F240B. It is better to confirm the in vivo anti-inflammatory activity of F240B using NLRP3-associated disease models, such as subcutaneous air pouch inflammation model (27) or gout inflammation model by injecting MSU crystals in joints (32). Another imitation of this study is only using single dose of F240B to evaluate the anti-inflammatory in vivo. Although F240B (IC 50 < 1 µM) is more effective to inhibit NLRP3 inflammasome than its analogue 4-HAB (IC 50~2 0 µM) in macrophages, without comparison of the in vivo dose-dependent inhibition of F240B we cannot conclude that F240B has more effective anti-inflammatory effects than 4-HAB, and more detailed investigation is need.
In summary, we have synthesized a new polyenylpyrrole derivative F240B and demonstrated that it is a potential antiinflammatory agent that inhibits the activation of NLRP3 inflammasome by inducing autophagy in macrophages ( Figure 11). We further demonstrated that F240B exerts in vivo anti-inflammatory activity in a mouse model of uric acid crystalinduced peritonitis, which is an NLRP3 inflammasome-associated disorder (33). As abnormal activation of the NLRP3 inflammasome leads to a broad range of inflammatory disorders, F240B has the potential to ameliorate NLRP3-associated diseases, including chronic kidney disease (34)(35)(36), inflammatory bowel disease (37) and neurodegenerative disorders (38). However, to assess the therapeutic potential of F240B, in vitro safety pharmacology studies and the in vitro and in vivo pharmacokinetics of F240B should be addressed.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/Supplementary Material; further inquiries can be directed to the corresponding authors.